B1MR34.SA BioMarin Pharmaceutical Inc.
- Market cap
- BRL 55.8B
- P/E
- -
- P/B
- 1.62x
- ROE
- 4.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is B1MR34.SA undervalued?
Graham numberThe Graham number of BioMarin Pharmaceutical Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioMarin Pharmaceutical Inc. fundamental analysis
No fundamental analysis for BioMarin Pharmaceutical Inc. yet.
BioMarin Pharmaceutical Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c…
Full company profileBioMarin Pharmaceutical Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioMarin Pharmaceutical Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 1.85B | 2.10B | 2.42B | 2.85B | 3.22B | 3.51B |
| Gross Profit | 1.38B | 1.59B | 1.89B | 2.27B | 2.62B | 2.72B |
| Operating Income | -74.3M | 161M | 186M | 484M | 409M | 481M |
| EBITDA | - | 265M | 310M | 651M | 573M | 790M |
| Net Income | -64.1M | 142M | 168M | 427M | 349M | 301M |
| EPS | -0.35 | 0.76 | 0.89 | 2.24 | 1.81 | 1.55 |
| Balance Sheet | ||||||
| Total Assets | 6.00B | 6.38B | 6.84B | 6.99B | 7.59B | 11.7B |
| Total Liabilities | 1.74B | 1.77B | 1.89B | 1.33B | 1.51B | 5.40B |
| Shareholders' Equity | 4.27B | 4.60B | 4.95B | 5.66B | 6.09B | 6.32B |
| Cash & Short-term Investments | 587M | 1.29B | 1.07B | 1.14B | 1.56B | 874M |
| Cash Flow | ||||||
| Operating Cash Flow | 305M | 176M | 159M | 573M | 828M | 778M |
| Capital Expenditure | 119M | 132M | 108M | 97.4M | 111M | 110M |
| Free Cash Flow | 185M | 44.4M | 51.6M | 475M | 717M | 667M |
| Ratios | ||||||
| ROE | -1.5% | 3.1% | 3.4% | 7.5% | 5.7% | 4.8% |
| ROA | -1.1% | 2.2% | 2.5% | 6.1% | 4.6% | 2.6% |
| Net Profit Margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% | 8.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioMarin Pharmaceutical Inc. dividends
BioMarin Pharmaceutical Inc. has not paid dividends in the last 5 fiscal years.
Who owns BioMarin Pharmaceutical Inc.
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 387M
- Free float 193M
BioMarin Pharmaceutical Inc. company profile
- Company name
- BioMarin Pharmaceutical Inc.
- Ticker
- B1MR34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3,221
- Fiscal year end
- December
- Address
- 770 Lindaro Street, San Rafael, CA, United States, 94901
- Phone
- 415 506 6700
- Website
- biomarin.com
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
BioMarin Pharmaceutical Inc. management
10- Mr. Alexander HardyPresident, CEO & Director · born 1969
- Mr. Brian R. Mueller CPACFO & Executive VP of Finance · born 1974
- Dr. C. Greg Guyer Ph.D.Executive VP & CTO · born 1962
- Ms. Cristin HubbardExecutive VP & Chief Commercial Officer
- Dr. Gregory Friberg M.D.Executive VP and Chief Research & Development Officer
- Ms. Rashmi Eshwar RamchandaniVP, Chief Accounting Officer & Principal Accounting Officer · born 1979
- Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early Development
- Mr. Arpit DaveExecutive Vice President, Chief Digital & Information Officer
- Mr. George Eric Davis J.D.Executive VP, Chief Legal Officer & Secretary · born 1971
- Ms. Cara Bauer Ph.D.Executive VP & Chief People Officer